Elevated tumor NOS2/COX2 promotes immunosuppressive phenotypes associated with poor survival in ER- breast cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Tumor NOS2/COX2 coexpression predicts poor outcomes in ER- breast cancer by suppressing the immune system. Targeting COX2 may enhance T-cell responses against aggressive tumors.
Area Of Science
- Oncology
- Immunology
- Cancer Research
Background
- Tumor immunosuppression critically impacts patient survival and treatment effectiveness.
- Coexpression of NOS2 and COX2 in tumors is a strong indicator of poor prognosis in estrogen receptor-negative (ER-) breast cancer.
- This coexpression drives tumor progression through metastasis, drug resistance, enhanced cancer stemness, and immune evasion.
Purpose Of The Study
- To investigate the spatial relationship between NOS2/COX2 expression and T-effector (TEff) cell infiltration in ER- tumors.
- To understand the mechanisms by which NOS2 and COX2 contribute to immune suppression and poor survival.
- To evaluate the therapeutic potential of targeting NOS2/COX2 in preclinical models.
Main Methods
- Analysis of spatial distribution of NOS2, COX2, B7H4, and immune cells (CD3+CD8+PD1- TEff, TRegs, CD4+ T cells, macrophages) in ER- tumors.
- Correlation of immune cell landscape with patient survival outcomes.
- Pharmacological inhibition of COX2 and genetic deficiency of NOS2 in a 4T1 breast cancer mouse model.
Main Results
- A distinct spatial landscape of NOS2/COX2 and TEff cells correlated with poor survival in ER- tumors.
- NOS2 localized to the tumor margin, while COX2 and B7H4 were found in immune-desert regions lacking TEff cells.
- Higher NOS2/COX2 to TEff cell ratios predicted worse outcomes; COX2 inhibition increased CD8+ TEff/TReg ratio and infiltration, unlike Nos2 deficiency.
Conclusions
- Tumor NOS2/COX2 coexpression is central to immune evasion in ER- breast cancer, particularly through exclusion of CD8+ T-effector cells.
- COX2 inhibition shows promise in overcoming immune suppression and enhancing anti-tumor immunity.
- Combination strategies targeting NOS2/COX2 with immunotherapy may offer new treatment avenues for aggressive, drug-resistant ER- breast tumors.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...